A new study by Tara Arouchian et al. aims to report and evaluate the incidence of pathogenic germline variants in pNEN, retrospectively analysing germline testing data from 129 patients, to elucidate a more comprehensive genetic profile. Read the full research: doi.org/10.1530/EO-25-0088

🆕 Join the Endocrine Oncology Reviewer Board Gain experience in peer review and academic publishing with a society-owned journal. Open to researchers in basic, translational and/or clinical research on hormones and cancer. Send your CV to [email protected] to be considered.

A new case report by Anna Battistella et al. describes a rare case of mesenteric primary mesenteric paragangliomas (PGLs) that was preoperatively diagnosed as a nodal metastasis from an occult ileal NET, leading to extensive but ultimately unnecessary investigations. 🔗 doi.org/10.1530/EO-25-0117

New research by Elisa Lamback et al. compares the expressions of POMC-processing genes across corticotroph tumour (CT) subtypes to elucidate mechanisms underlying their functional spectrum, identifying a potential new regulator of the secretory properties of CTs. 🔗 doi.org/10.1530/EO-26-0003

A new retrospective study by Wallace Chow et al. reports the incidence, survival outcomes and potential predictive factors of therapy‑related myeloid neoplasms (t‑MNs), a rare but fatal complication of PRRT toxicity, from a quaternary referral academic NEN centre. 🔗 doi.org/10.1530/EO-25-0107

What is the clinical value of I‑123 scans in follow‑up for DTC? A new study evaluates how I‑123 diagnostic scintigraphy influences decision‑making in DTC follow‑up & whether the multidisciplinary team influences subsequent clinical pathways. ➡️ Read the full article: doi.org/10.1530/EO-25-0105

Metastatic ACC has a poor prognosis and complete responses are rare. A new article suggests that streptozotocin & mitotane (or Sz alone) could be a valuable second-line option for advanced ACC after disease progression or toxicity with first-line treatments. #OpenAccess: doi.org/10.1530/EO-25-0047

New research examines vitamin D receptor (VDR) biology across cell-of-origin subtypes of diffuse large B-cell lymphoma. Findings suggest tumoural VDR & cell‑of‑origin classification may help identify patients who could benefit from VitD₃. Read the article #OpenAccess: doi.org/10.1530/EO-25-0057

Monitoring renal and bone marrow function in cancer patients is vital, yet current clinical tools remain limited. New research evaluates whether non‑invasive MRI and ¹⁸F‑FLT PET‑MR can detect early renal and bone marrow effects in NET patients receiving ¹⁷⁷Lu‑DOTATATE. 🔗 doi.org/10.1530/EO-25-0036

🏃‍♀️‍➡️ A new retrospective study by Carla Colombo et al. explores how baseline physical activity and its maintenance relate to treatment safety and efficacy in patients with advanced thyroid cancer on kinase inhibitor therapy. Read the full article #OpenAccess: doi.org/10.1530/EO-2...

A new study by Julie Hallet et al. examines the association between patient-reported outcome measures (PROMs) & urgent healthcare use, with a view to inform better support strategies for patients diagnosed with neuroendocrine tumours (NETs). 🔓 Read the full article: doi.org/10.1530/EO-25-0050

🧬 A new case report by Einas Mohamed et al. describes three carriers of germline SDHA variants, illustrating how clinical context is essential when deciding whether a variant should lead to surveillance or family testing. 🔗 Read the full report #OpenAccess: doi.org/10.1530/EO-25-0048

What is the prognostic value of primary tumor size in duodenal neuroendocrine neoplasms (dNENs) ≤20 mm? A new population-based study aims to clarify the prognostic and clinicopathologic role of tumor size in duodenal NENs ≤ 20 mm using SEER data. Read the research: doi.org/10.1530/EO-25-0108

A new case report by Alexandra Zueva et al. demonstrates the heterogeneity seen in PTHrP-secreting pancreatic neuroendocrine tumours (Pan-NETs) - an exceptionally rare cause of humoural hypercalcaemia of malignancy. Read the full report: doi.org/10.1530/EO-25-0085

A newly published case report by James M McNeil et al. describes an individual with a giant GH and PRL-PA, who achieved significant biochemical (GH and PRL), and partial structural, ophthalmological and clinical responses following upfront cabergoline monotherapy. 🔗 doi.org/10.1530/EO-25-0077

#FEBRUARY11 spotlights the global efforts to close gender gaps in STEM & empower women‑led innovation. We highlight the outstanding women advancing NET science through our Women in NET Science Collection. Explore the collection or contribute an article: eo.bioscientifica.com/page/Women-in-NETs

We’re launching Editor’s Exclusive to share expert insight from leaders on the Endocrine Oncology Editorial Board. In this instalment, Prof. Ashley Grossman explores recent advances & key developments likely to shape the field. eo.bioscientifica.com/page/exclusive/editors-exclusive

🆕 Insights to optimise outcomes with mitotane in pediatric patients with adrenocortical carcinoma. A new study explores the associations between mitotane dosage, plasma drug levels & anthropometric measurements, highlighting how these factors influence dosage. 🔓 doi.org/10.1530/EO-24-0081

Did you attend ENS@T 2025? Submit your work to our Special Collection! We're inviting submissions of original research, mini reviews, review articles, and case reports. Plus, there is a £300 'Best Paper' Award! More info: eo.bioscientifica.com/page/ENSAT/2...

🍽️ Call for Papers: Nutrition and Metabolism in Neuroendocrine Tumours We’re excited to announce a Special Collection dedicated to exploring the interplay between nutrition, metabolism, and NET biology. 🌐 Learn more & submit here: eo.bioscientifica.com/page/1545/nu...

Why publish in Endocrine Oncology? 1️⃣ Fully OA ensuring your work reaches a global audience 2️⃣ No APCs during launch so you can currently publish for free! 3️⃣ Society-owned, led by Prof. Justo P. Castaño & supported by an international Editorial Board Explore the journal: eo.bioscientifica.com/

Distinguishing NET G3 from NEC in the GEP region is challenging. A new study by Zandra Ankers et al. investigates markers that may improve this distinction and assesses whether this subclassification has diagnostic or prognostic value. 🔗 Read the article: doi.org/10.1530/EO-25-0065

⚠️ How should we define carcinoid crisis? New research by Maribel del Olmo-García et al. suggests that prolonged intraoperative hypotension is the most clinically relevant definition. Explore valuable insights into the definition and management of carcinoid crisis: doi.org/10.1530/EO-25-0034

🔬 PanNET enucleation: 40+ years of outcomes A retrospective study (1979–2021, median follow-up 153 months) shows excellent exocrine function preservation with median OS of 203 months. 👉 Read more: doi.org/10.1530/EO-25-0035 ✨ Part of Women in Neuroendocrine Tumour Science Special Collection

🚨Extracellular vesicles & particles (EVPs) are emerging as key modulators of neuroendocrine tumour behaviour. Contribute to our Special Collection dedicated to insights that deepening our understanding of EVPs in NETs. eo.bioscientifica.com/page/NET/ext... Send proposals to [email protected]

✨ Last week’s Society for Endocrinology's Hormone Dependent Cancer Conference sparked inspiring discussions. We're keeping up the momentum with the Hormone‑Dependent Cancers: from Bench to Bedside Special Collection. 🌐 eo.bioscientifica.com/page/HDC/hormonedependent-cancers-from-bench-to-bedside

Call for Papers: Tumour Heterogeneity in Neuroendocrine Neoplasms We invite you to contribute to our latest Special Collection exploring the complexity of tumour heterogeneity in neuroendocrine neoplasms (NENs). eo.bioscientifica.com/page/NENs/tumour-heterogeneity-in-neuroendocrine-neoplasms

Next week, Society of Endocrinology will host the Hormone-Dependent Cancer Conference. As sponsors, we've launched a Special Collection to complement the event. We invite research submissions that advance our understanding of hormone-dependent cancers. 📧 [email protected] 🌐 bit.ly/4oyll2v

New research by K Wang et al. suggest that paltusotine, a novel somatostatin analogue, could be continued during peptide receptor radionuclide therapy (PRRT) in patients with metastatic gastro-enteropancreatic neuroendocrine tumours (GEP-NETs). 🔗 Explore the findings: doi.org/10.1530/EO-25-0041

Cytoreductive surgery is standard for metastatic phaeochromocytomas & paragangliomas. 177Lu‑DOTATATE PRRT could offer a safe, effective option for inoperable cases. Kalyan Mansukhbhai Shekhda et al. report encouraging PFS & improved health-related QoL following PRRT. 🔗 doi.org/10.1530/EO-25-0019

🔬 Molecular testing is changing how we assess thyroid cancer risk. New research by Alexander R Goldberg et al. explores the clinical & molecular characteristics of cytologically non-malignant thyroid tumors with multiple high-risk mutations, revealing aggressive behaviour. #ThyroidCancer

🧬 New research by Julio Ricarte Filho et al. provides the first comprehensive molecular and immune comparison of oncocytic thyroid cancer and follicular thyroid cancer, offering new insights into their biological differences. 👉 Read the full research: doi.org/10.1530/EO-25-0026

Explore influential studies in endocrine-related cancers published in Endocrine Oncology, a society-owned journal, covering topics from prolactinomas to thyroid tumours 👉 eo.bioscientifica.com/page/top-cited/top-cited-articles Endocrine Oncology is proudly endorsed by BACR.

New research by Kalyan Vamshi Vemulapalli et al. demonstrates that ⁶⁸Ga-DOTA-TATE PET/CT offers a higher detection rate for dpNETs in MEN1 patients compared to conventional CT and MRI - resulting in significant changes to clinical management. 📖 Read the full article: doi.org/10.1530/EO-25-0060

Systemic therapy for metastatic adrenocortical carcinoma (mACC) remains a challenge. A new meta-analysis by S Shekar et al. synthesises prospective trial data to: 💡 Benchmark survival and response 💡 Compare treatment efficacy 💡 Identify gaps for future trials 🔗 doi.org/10.1530/EO-25-0027

Be part of the global #neuroendocrinecancer research conversation in Boston, November 17-19. The NETRF Annual Research Symposium brings together expert researchers to share leading-edge science and learn from each other. Register now: bit.ly/4nQ9goU #NETresearch #cancerresearch

🆕 A retrospective case series by Eleni Armeni et al. from Royal Free Hospital explores the diagnostic & therapeutic complexities of glucagonomas, offering a valuable reference point for clinicians & researchers navigating the field. 🔗Read the article: doi.org/10.1530/EO-24-0083

🌐 Endocrine Oncology has joined LinkedIn! We're excited to connect with the global endocrine oncology community in a new space. Follow us for the latest journal articles, special collections and key updates. 🌐 linkedin.com/company/endocrine-oncology/

New research by Kim Dijke et al. (@nkinl.bsky.social) highlights the differences in disease course of appendiceal NETs & appendiceal goblet cell adenocarcinomas, supporting the exclusion of aGCAs from the group of NENs in the 5th #WHO classification. Read the research: doi.org/10.1530/EO-25-0028

🧠Contribute to Endocrine-Related Cancer's new Special Collection on pituitary tumours! We welcome basic, translational & clinical studies that advance understanding & showcase innovations in the field. 📩Submit your proposal to: [email protected] 🌐More info: bit.ly/4mUXslc

🆕 Tumour Heterogeneity in Neuroendocrine Neoplasms Special Collection #NENs We’re seeking cutting-edge research on the biological & clinical characterisation of NEN heterogeneity, highlighting its impact on prognosis & treatment outcomes. 🌐 More info: bit.ly/4lWsJTc 📢 Submit: [email protected]

🧬 A new systematic review and meta-analysis by M P Aguiar et al. links estrogen-related gene polymorphisms to ovarian cancer occurrence/susceptibility, uncovering variants in CYP17A1, COMT and GSTP1 that may be associated with risk. 🔗 Explore the review #OpenAccess: doi.org/10.1530/EO-25-0007

🌱Endocrine-Related Cancer is officially on LinkedIn! Follow our new profile to stay up to date with the latest articles, special collections and updates from the journal. 🌐 linkedin.com/company/endocrine-related-cancer/ #MedSky #CancerResearch #EndocrineOncology #HormoneCancers

🔬 Latest research by Lara Toffoli et al. investigates the impact of FAK inhibition on GI neuroendocrine tumors (GI-NETs) demonstrating its pivotal role in pathogenesis of GI-NETs & supporting its therapeutic targeting. 👉 Read the full article: doi.org/10.1530/EO-2...

Your research can help advance hormone-dependent cancer treatment and improve patient care. Abstract submissions close Monday 15 Sept: bit.ly/4fqWdqL

Our study on FAK inhibition in GI-NETs reveals its dual role in tumor growth, invasion, and even epigenetic regulation. Grateful to my team for their dedication, and to all colleagues, collaborators, and friends who supported us along the way. 🙏 📄 Open Access: eo.bioscientifica.com/view/journal...

💗 Proud of my young research group 💗 Despite limited resources and many challenges, we published our latest work in @endocrineoncology.bsky.social — an emerging journal with a distinguished editorial board of leading experts. #CancerResearch #FAK #NeuroendocrineTumors #TeamScience

Sponsored by @netrf.org, this $100,000 grant is designed to help an early-career, basic or clinical scientist conduct novel and innovative #NETs research. Learn more: mierf.org/to-apply/ #neuroendocrinecancer #earlycareerresearcher

📈Incidence & prevalence of neuroendocrine neoplasms continues to rise globally. A new review by Jessica Mangion et al. explores global epidemiological data, reviewing trends & differences in incidence rates to improve our understanding of this rise. 🔗 doi.org/10.1530/EO-25-0039

🔍Somatostatin analogues (SSA) can unmask insulinoma in presumed non-functional GEP-NETs. A new case report by Isuru Gamage et al. (@petermaccc.bsky.social‬) presents two cases where SSA unmasked hypoglycaemia due to insulinoma. 📖 Check out the full report: doi.org/10.1530/EO-2...